Globus Medical (GMED) Stock

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a top company in musculoskeletal solutions, will share its financial results for the fourth quarter and the entire year ending December 31, 2024, after the market closes on Thursday, February 20, 2025. You can find the release on the Globus Medical website at www.investors.globusmedical.com.

Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.

GMED's successful merger with NuVasive and its strong results in the musculoskeletal solutions market are promising for investors. This combination creates valuable opportunities for growth. Overall, the outlook appears positive.

Globus Medical (GMED) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

Globus Medical is experiencing significant growth in various areas of its product range, including expandables, biologics, minimally invasive screws, 3D printed implants, and cervical products.

AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a top company in musculoskeletal solutions, has shared its early sales results for the fourth quarter and the entire year ending December 31, 2024. The company projects that its sales for the fourth quarter of 2024 will be around $657.0 million, which is a 6.6 percent rise compared to the same quarter in 2023. For the full year 2024, sales are expected to reach about $2.52 billion, marking a 60.6 percent increase from the previous year.

No matter if you focus on value, growth, or momentum investing, discovering solid stocks is simpler with the Zacks Style Scores, which is a key part of the Zacks Premium research service.

The merger between Globus Medical and NuVasive, along with a solid financial situation, gives investors a reason to feel positive.

New developments and strong growth in international markets are boosting investors' confidence in Tandem Diabetes.